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Abstract
Recent evidence has demonstrated that regulatory T cells (Treg) were enriched in the tumor sites of patients with B-cell
non-Hodgkin lymphoma (NHL). However, the causes of enrichment and suppressive mechanisms need to be further
elucidated. Here we demonstrated that CD4
+CD25
+FoxP3
+CD127
lo Treg were markedly increased and their phenotypes
were different in peripheral blood (PB) as well as bone marrow (BM) from newly diagnosed patients with B-cell NHL
compared with those from healthy volunteers (HVs). Involved lymphatic tissues also showed higher frequencies of Treg than
benign lymph nodes. Moreover, the frequencies of Treg were significantly higher in involved lymphatic tissues than those
from PB as well as BM in the same patients. Suppression mediated by CD4
+CD25
+ Treg co-cultured with allogeneic CFSE-
labeled CD4
+CD25
2 responder cells was also higher in involved lymphatic tissues from B-cell NHL than that mediated by
Treg from HVs. In addition, we found that malignant B cells significantly induced FoxP3 expression and regulatory function
in CD4
+CD25
2 T cells in vitro. In contrast, normal B cells could not induce the conversion of CD4
+CD25
2 T cells to Treg. We
also showed that the PD-1/B7-H1 pathway might play an important role in Treg induction. Taken together, our results
suggest that malignant B cells induce the conversion of CD4
+CD25
2 T cells to Treg, which may play a role in the
pathogenesis of B-cell NHL and represent a promising therapeutic target.
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Introduction
B-cell non-Hodgkin lymphomas (NHL) are common lymphoid
malignancies in which malignant B cells arrested at varying stages
of differentiation often involve lymph nodes (LNs) and occasionally
extranodal tissues. Besides malignant cells, T cells are usually
present in the tumor microenvironment, which commonly include
regulatory T cells (Treg) [1], suggesting that Treg may play a role
in regulating tumor growth in patients with B-cell NHL.
It is becoming clear that tumors may induce immunologic
tolerance by promoting the expansion, recruitment and activation
of Treg [2]. Treg, which account for about 5% to 10% of
peripheral CD4
+ T cells in both mice and humans, include
naturally occurring CD4
+CD25
+ Treg as well as peripherally
induced CD4
+ Treg [3,4]. Recently, Helios, a member of the
Ikaros family, was reported as a marker to express on the naturally
occurring Treg, but not those induced Treg [5]. Sustained high
surface expression of CD25, cytotoxic T-lymphocyte–associated
antigen 4 (CTLA-4) and glucocorticoid-induced TNFR-related
protein (GITR) expression are features of suppressive Treg [6,7].
Expression of forkhead box P3 (FoxP3), a member of the forkhead-
winged helix family of transcription factor, has been demonstrated
to be a lineage marker for murine and human Treg [7,8].
Furthermore, they have been found that Treg express lower levels
of CD127 than the majority of other CD4
+ T cells, and CD127
expression inversely correlates with FoxP3 expression in our own
and others’ previous studies [9,10,11]. Thus, the gate of
CD4
+CD25
+FoxP3
+CD127
lo is currently one of the best methods
to define for Treg using flow cytometry [12,13].
Treg have been shown to be overrepresented in patients with
various cancers and able to suppress antitumor immune response
[14,15,16,17]. In B-cell NHL, several studies have also shown that
increased frequencies of CD4
+CD25
+ Treg in peripheral blood
(PB) and involved LNs mediated vigorous suppressive activity
compared to those from healthy volunteers (HVs) [18,19].
Although many studies have shown that Treg play an importance
role in the immune system, the exact mechanism of suppression by
Treg is still poorly understood. It has been shown that Treg can be
efficiently recruited and expanded in the tumor microenvironment
and suppress effector function of cytotoxic T cells as well as NK
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already demonstrated that Treg cell-mediated immunosuppression
is one of the crucial tumor immune evasion mechanisms and the
main obstacles of successful cancer immunotherapy [11,25]. These
studies suggest that Treg could be an attractive target for anti-
cancer therapy in both humans and animal models.
In some kinds of B-cell NHL, such as mantle cell lymphoma
(MCL), malignant B cells usually infiltrate other parts of the body
including bone marrow (BM) when they are diagnosed. Here we
measured the frequencies and suppressive function of Treg in PB,
BM and involved lymphatic tissues of patients with B-cell NHL
and determined whether malignant B cells could induce the
conversion of Treg from CD4
+CD25
2 T cells. We found that the
elevated frequencies and suppressive function of Treg might be
related to the pathogenesis of B-cell NHL, and the conversion of
Treg was induced by malignant B cells through the PD-1/B7-H1
pathway in some kinds of B-cell NHL, especially in MCL.
Materials and Methods
Patients
Between September 2008 and March 2011, 32 newly diagnosed
patients with B-cell NHL (age range: 33 to 81 years, mean=59,
SD=14) were recruited from the First Affiliated Hospital of
Wenzhou Medical College. All protocols and experiments were
approved by the First Affiliated Hospital of Wenzhou Medical
College institutional review board for clinical experiments and use
of human samples; written consents were obtained from all
subjects participated in this study in accordance with the
Declaration of Helsinki protocol. The age-matched control group
comprised of 18 HVs (age range: 35 to 72 years, mean=55,
SD=13) and 4 individuals with benign lymphadenopathy (age
range: 41 to 65 years, mean=52, SD=10). Patient characteristics
are described in Table 1. Although various classification systems
exist for determining specific histological subtypes, B-cell NHL is
usually divided into indolent and aggressive forms. So we divided
these patients into tow groups: indolent and aggressive.
Reagents
The following fluorochrome-conjugated antibodies were used
for immunostaining: anti-CD25-FITC, anti-CD25-PE, anti-CD4-
PerCP, anti-FoxP3-PE, anti-FoxP3-Alexa FluorH 647, anti-
CD127-Alexa FluorH 647, anti-CD45RA-PE, anti-CD45RO-PE,
anti-HLA-DR-FITC, anti-CD62L-PE, anti-CD95-PE, anti-
CTLA-4-PE, anti-PD-1-PE, anti-CD3-PerCP, anti-CD8-FITC,
anti-IFN-c-PE, anti-IL-4-PE, anti-IL-2-PE, anti-IL-17-PE, anti-
CD19-FITC, anti-CD19-APC, anti-Lambda-FITC, anti-Kappa-
PE, anti-B7-H1-PE and appropriate negative controls all from BD
(San Diego, CA). Anti-GITR-FITC and recombinant human PD-
1 Fc were obtained from R&D systems (Minneapolis, MN).
CD4
+CD25
+ Regulatory T-cell Isolation Kit, B Cell Isolation Kit
II and magnetic-activated cell sorting columns were purchased
from Miltenyi Biotec (Bergisch Gladbach, Germany). Carboxy-
fluorescein diacetate succinimidylester (CFSE) was obtained from
Alexis (Lausen, Switzerland). Phorbol 12-myristate 13-acetate
(PMA), ionomycin and brefeldine A (BFA) were purchased from
Sigma-Aldrich (St Louis, MO).
Immunostaining and flow cytometric analysis
Fresh lymphatic tissue specimen was cut into approximately
1 mm pieces and disaggregated mechanically into a single cell
suspension by rotating knifes (Medimachine; Dako, Hamburg,
Germany). The cell suspension was subsequently centrifuged
through Ficoll-Hypaque to isolate mononuclear cells. Peripheral
blood mononuclear cells (PBMCs) and bone marrow mononuclear
cells (BMMCs) were isolated from PB and BM samples by Ficoll-
Hypaque centrifugation, respectively. Cells were incubated with
fluorochrome-conjugated antibodies which recognize and bind to
various cell surface antigens. For intracellular FoxP3 staining, cells
were first stained with appropriate surface antibodies, washed, and
then fixed, permeablized and stained with anti-FoxP3 for 30 min
at 4uC in the dark. For intracellular cytokine staining, cells were
stimulated with PMA (20 ng/mL) and ionomycin (1 mg/mL) for
5 hours in the presence of BFA (10 mg/mL). Samples were
Table 1. Clinical characteristics of patients with B-cell NHL.
Patient no. Sex Age,y
Histologic
diagnosis Tissue used
1 M 47 DLBCL PBMC, BM
2 M 72 MCL PBMC, BM (new)
3 M 43 MCL PBMC, BM (new)
4 F 46 DLBCL PBMC, Node (new)
5 M 57 MCL PBMC, BM
6 M 65 MZL PBMC, Node (new)
7 F 65 SLL PBMC, BM, Node
(new)
8 M 70 DLBCL PBMC, BM
9 M 53 SLL PBMC, BM (new)
10 M 76 SLL PBMC, BM (new)
11 M 63 MCL PBMC, BM (new)
12 M 36 DLBCL PBMC, BM
13 M 33 DLBCL PBMC, BM, Node
(new)
14 F 58 DLBCL PBMC, BM (new)
15 M 60 MZL PBMC, BM, Node
(new)
16 M 49 Follicular NHL, grade
1
PBMC, Node (new)
17 F 44 DLBCL PBMC, BM
18 F 56 DLBCL PBMC, BM, Spleen
(new)
19 M 78 MCL PBMC, BM
20 M 78 DLBCL PBMC, BM, Node
(new)
21 M 35 MZL PBMC, BM (new)
22 M 54 DLBCL PBMC, BM
23 M 71 DLBCL PBMC, BM (new)
24 M 49 DLBCL PBMC, BM, Node
(new)
25 F 66 DLBCL PBMC, BM (new)
26 F 73 DLBCL PBMC, BM
27 M 53 MCL PBMC, BM (new)
28 M 33 DLBCL PBMC, BM
29 M 57 DLBCL PBMC, Node (new)
30 F 73 DLBCL PBMC, BM (new)
31 F 80 DLBCL PBMC, BM
32 M 81 DLBCL PBMC, Node (new)
DLBCL indicates diffuse large B-cell lymphoma; MCL, mantle cell lymphoma;
new, a diagnosis of lymphoma with no previous history of lymphoproliferative
disease; MZL, marginal zone lymphoma; and SLL, small lymphocytic lymphoma.
doi:10.1371/journal.pone.0028649.t001
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FITC. Then, the cells were fixed, permeabilized and stained with
anti-FoxP3-Alexa FluorH 647, anti-IFN-c-PE, anti-IL-4-PE, anti-
IL-2-PE, and anti-IL-17-PE. A minimum of 50,000 cells were
analyzed for each sample using flow cytometry (FACSCalibur;
BD).
Suppression assay
CD4
+CD25
+ and CD4
+CD25
2 T cells were obtained using
CD4
+CD25
+ Regulatory T cell Isolation Kit according to
manufacturer’s protocols. The suppressive function of CD4
+CD25
+
Treg was assessed using mixed leukocyte culture assay. Briefly,
CD4
+CD25
+ T cells were co-cultured with allogeneic CFSE
(5 mmol/L)-labeled CD4
+CD25
2 T cells in the presence of
c-irradiated (30 Gy) PBMCs (as antigen-presenting cells) for 4 days,
with each population 2610
5 cells. After 4 days of co-culture, the
cells were washed and the CFSE intensity was analyzed by flow
cytometry.
Induction assay
CD19
+ cells from PBMCs, BMMCs and involved lymphatic
tissues were isolated by using B Cell Isolation Kit II according to
manufacturer’s instructions. CD4
+CD25
2 and CD19
+ cells were
co-cultured in 96-well flat-bottom plate at a density of 2610
5
cells/well for each cell type. These cells were cultured in X-
ViVO
TM 15 medium (Cambrex, Walkersville, MD) supplemented
with 2 mM L-glutamine, 100 IU/ml IL-2 and 10% BSA in the
presence or absence of human PD-1 Fc (20 mg/ml) or anti-human
B7-H1 (10 mg/ml; eBioscience, San Diego, CA). After 5 days,
cultured cells were harvested and stained for CD4 and
intracellular FoxP3, and analyzed by flow cytometry.
Statistical analysis
Quantitative data were expressed as mean 6 standard deviation
(SD). The frequencies of Treg for statistical differences in PB, BM
and involved lymphatic tissues were analyzed with a one-way
analysis of variance (ANOVA). Data about the conversion of Treg
through PD-1/B7-H1 pathway were analyzed using pair t-test. A p
value of less than 0.05 was considered significant.
Results
Elevated frequencies of CD4
+CD25
+FoxP3
+CD127
lo Treg
in patients with B-cell NHL
To investigate a possible role of CD4
+CD25
+FoxP3
+CD127
lo
Treg in the immune system in B-cell NHL, both peripheral
tolerance and the tumor microenvironment, we measured the
frequencies of CD4
+CD25
+FoxP3
+CD127
lo Treg in PB, BM and
involved lymphatic tissues from patients with B-cell NHL. For
comparison, PBMCs from HVs and cells from benign LNs were
used as controls. As shown in Figure 1A and 1B, the elevated
frequencies of CD4
+CD25
+FoxP3
+CD127
lo Treg could be detected
in involved lymphatic tissues (26.8%610.1% of the total CD4
+ T
cells, range, 12.4%–48.7%, n=11) and PB (17.9%67.3%, range,
7.7%–41.2%, n=32) and BM (19.1%69.4%, range, 7.4%–43.9%,
n=27) compared with those from PBMCs from HVs (5.3%61.5%,
range, 3.2%–9.1%, n=18) or benign LNs (7.9%62.1%, range,
6.2%–10.9%, n=4). The Treg frequencies in involved lymphatic
tissues (28.1%610.6%, range, 20.6%–40.7%) were higher
compared to PB (18.4%66.4%, range, 7.7%–25.3%) or BM
(17.8%64.0%, range, 14.6%–25.6%) in the same patients (n=6,
Figure 1C), indicating that preferential accumulation of Treg in
involved lymphatic tissues occurred. Furthermore, patients with
aggressive B-cell NHL (n=25; DLBCL, n=19; and MCL, n=6)
had higher frequencies of Treg in PB than patients with indolent B-
cell NHL (n=7; MZL, n=3; and SLL, n=3; and FL, n=1).
However, there was no significant difference in BM or involved
lymphatic tissues between indolent and aggressive B-cell NHL
(Figure 1D). Asthis is generallytrue forB-cellNHLwhichmayhave
BM involvement of malignant B cells, we analyzed the influences of
BM involvement on the Treg frequencies. Patients with BM
involvement (n=9; MCL, n=5; and DLBCL, n=3; and SLL,
n=1) had higher frequencies of Treg in BM than patients without
BM involvement (n=18). Moreover, there was no significant
difference in involved BM and involved lymphatic tissues
(Figure 1E).
Surface phenotype of CD4
+CD25
+CD127
lo Treg
As the suppressive function of Treg is associated with its surface
receptors [6,26,27], we evaluated a possible role of surface markers
in CD4
+CD25
+CD127
lo Treg and CD4
+ T cells presented in
patients with B-cell NHL. As shown in Figure 2A and 2B,
significant differences in phenotypes were found between patients
with B-cell NHL and HVs. The CD4
+CD25
+CD127
lo Treg had
high expression of CD45RO combined with low expression of
CD45RA and no difference in the expression of CD45RA and
CD45RO between patients with B-cell NHL and HVs. The
expression levels of HLA-DR, CD62L and CD95 were reduced in
Treg of PB, BM and involved lymphatic tissues from patients with
B-cell NHL compared with those from PB samples of HVs and
benign LNs. In contrast, the expression levels of CTLA-4 and
GITR in Treg of PB, BM and involved lymphatic tissues from B-
cell NHL were significantly higher than those in PB samples from
HVs and benign LNs. Furthermore, the expression levels of
CTLA-4 and GITR in Treg from involved lymphatic tissues were
slightly higher than those from PB or BM in patients with B-cell
NHL. Similar expression levels of CTLA-4 and GITR occurred in
both PB and BM samples. The expression of PD-1 was higher in
Treg from BM samples of patients with B-cell NHL than those
from HVs. In addition, the expression of PD-1 in Treg was also
higher in involved lymphatic tissues from patients with B-cell NHL
than those from benign LNs. Notably, the infiltrating CD4
+ T cells
expressed high levels of PD-1 in the involved lymphatic tissues,
indicating that PD-1 was mainly expressed on the CD4
+CD25
2
cells, but not on Treg.
Functional characterization of CD4
+CD25
+FoxP3
+CD127
lo
Treg from patients with B-cell NHL
As the functional hallmark of Treg is their ability to suppress
immune responses driven by effector T cells, we performed a
typical in vitro suppression assay to examine the suppressive
capacity of these cells. The CD4
+CD25
+ T cells used in these
experiments were indeed confirmed FoxP3
+ in equal proportions
and not contaminated by activated non-Treg CD4
+ T cells. CFSE-
labeled CD4
+CD25
2 T cells (responding cells) were co-cultured
with CD4
+CD25
+ T cells (stimulating cells) in the presence or
absence of c-irradiated PBMCs for 4 days. At a suppressor/
responder ratio of 1:1, the suppression of responder cell
proliferation was higher in involved lymphatic tissues from patients
with B-cell NHL (n=4; patients 6, 7, 13, and 18)than PB or BM
samples from patients with B-cell NHL (patients 6, 7, 13, and 18
for PB, n=4; and patients 7, 11, 13, and 18 for BM, n=4) as well
as PB samples from HVs or benign LNs (Figure 3A). In addition,
Treg, irrespective of the source, could markedly inhibit the
proliferation of CD4
+CD25
2 T cells (Figure 3A).
Another inherent attribute of Treg is their disability to produce
and secrete proinflammatory cytokines such as IL-2, IFN-c, IL-4
and IL-17. We assessed the production of these cytokines in
Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
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+CD25
+FoxP3
+CD127
lo Treg in PB, BM and involved lymphatic tissues in patients with B-cell
NHL. (A) Dot plots were gated on CD4
+ T cells (based on forward and side scatter and CD4 staining). The number in the dot plot represents the
percentage of gated cells expressing the relevant marker. (B) Frequencies of CD4
+CD25
+FoxP3
+CD127
lo Treg in PB, BM and involved lymphatic tissues
from patients with B-cell NHL and HVs were quantified using flow cytometric analysis. (C) Frequencies of CD4
+CD25
+FoxP3
+CD127
lo Treg in PB, BM
and involved lymphatic tissues from the same patients with B-cell NHL were measured as described earlier. (D) Frequencies of
CD4
+CD25
+FoxP3
+CD127
lo Treg in PB, BM and involved lymphatic tissues from indolent B-cell NHL patients and aggressive B-cell NHL patients
were measured as described earlier. (E) Frequencies of CD4
+CD25
+FoxP3
+CD127
lo Treg in BM and involved lymphatic tissues from patients with B-cell
NHL were measured as described earlier. Each open circle represents a single individual assessed in the respective group and numbers on the left of
horizontal bars represent the group means.
doi:10.1371/journal.pone.0028649.g001
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+FoxP3
+ T cell subset using intracellular cytokine staining
after stimulation with PMA/ionomycin. As showed in Figure 3B,
CD4
+FoxP3
+ T cells from involved lymphatic tissues of patients
with B-cell NHL (n=4; patients 6, 7, 13, and 18) were unable to
produce IL-2, IFN-c, IL-4 and IL-17 in response to strong PMA/
ionomycin stimulation. Similarly, CD4
+FoxP3
+ T cells from PB of
HVs could not produce these cytokines (data not shown). These
results indicated that both the inhibitory immune response and
produced cytokine profiles accorded to typical characteristics of
human Treg.
Malignant B cells induce CD4
+CD25
2 T cells into Treg in
vitro
To investigate why the frequencies of Treg were increased in
patients with B-cell NHL, sorted CD4
+CD25
2 cells from patient
samples (patients 5, 8, 11, 19, and 27 for BM, n=5; patients 7 and
24 for involved LN, n=2) were co-cultured with purified
autologous malignant B cells. The malignant B cells were verified
by flow cytometry to be clonally restricted, more than 90% of cells
expressed either kappa or lambda immunoglobulin, but not both.
We found that FoxP3
+ cells were markedly induced from
CD4
+CD25
2 T cells in the presence of autologous malignant B
cells. In addition, FoxP3
+ cells could not be induced from
CD4
+CD25
2 T cells in the presence of autologous normal B cells
from HVs (Figure 4A and 4B). Furthermore, we found that
FoxP3
+ cells were also induced from CD4
+CD25
2 T cells isolated
from HVs in the presence of malignant B cells, and FoxP3
+ cells
could not be induced from CD4
+CD25
2 T cells isolated from B-
cell NHL specimens (patients 5 and 11 for BM, n=2; patients 7
and 24 for involved LN, n=2) in the presence of normal B cells
(Figure 4C and 4D). Thus, these results indicated that the
conversion of Treg was dependent on malignant B cells,
irrespective of the origin of tissues, not T cells, which further
confirmed and extended the previous conclusions by other
researcher in involved LNs from FL [28].
B7-H1, a newly discovered member of the B7 family, is
expressed on monocytes or dendritic cells. We showed that the
expression of B7-H1 was higher in lymphoma B cells than normal
B cells (Figure 4E). Surprising, in patients 5, 11, 19, and 27, which
were MCL, blocking the interaction of PD-1 and B7-H1 using PD-
1 Fc or anti-B7-H1 antibody could partly inhibit the induction of
the CD4
+FoxP3
+ phenotype (Figure 4F). However, in patients 7,
8, and 24 (SLL, n=1; and DLBCL, n=2), blocking the
interaction of PD-1 and B7-H1 could not inhibit the induction
of the CD4
+FoxP3
+ phenotype. In a whole, blocking the PD-1/
B7-H1 pathway could reduce the generation of Treg (Figure 4G),
suggesting that PD-1/B7-H1 signaling may regulate the genera-
tion of Treg in B-cell NHL, especially in MCL.
Next, we investigated whether the converted Treg acquired the
regulatory function. As shown in Figure 5A, the converted Treg
could inhibit the proliferation of conventional CD4
+CD25
2 T
cells. Moreover, the converted FoxP3
+ cells produced the
background level of IL-2, IFN-c, IL-4 and IL-17, and the FoxP3
2
Figure 2. Surface phenotype of CD4
+CD25
+CD127
lo Treg and CD4
+ T cells obtained from patients with B-cell NHL and HVs.
Expression rates of various markers in PB of HVs (n=8), PB (n=8; patients 3, 4, 7, 8, 11, 13, 15, and 16), BM (n=8; patients 3, 8, 11, 12, 13, 17, 19, and
20)and involved lymphatic tissues (n=8; patients 4, 7, 13, 15, 16, 18, 20, and 24) from patients with B-cell NHL (n=8), and benign LNs (n=4). (A).
CD4
+CD25
+CD127
lo Treg. (B). CD4
+ T cells.
*P,0.05 vs Treg or CD4
+ T cells from PB of HVs;
DP,0.05 vs Treg or CD4
+ T cells from benign LNs;
#P,0.05
vs Treg or CD4
+ T cells from involved lymphatic tissues of B-cell NHL.
doi:10.1371/journal.pone.0028649.g002
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(Figure 5B). The two results suggest that the converted FoxP3
+
cells be endowed with the classical suppressive function.
Discussion
Treg can be recruited, expanded or converted in the tumor
microenvironment. However, little is currently known about the
cause of strong peripheral tolerance in patients with B-cell NHL.
In this study, we demonstrated an elevated frequency of
CD4
+CD25
+FoxP3
+CD127
lo Treg in PB, BM and involved
lymphatic tissues from patients with B-cell NHL, and we also
showed that these cells could be potently induced by lymphoma B
cells in vitro.
We found a significantly higher percentage of CD4
+CD25
+
FoxP3
+CD127
lo Treg presented in PB as well as BM samples from
B-cell NHL compared with PB samples from HVs. Furthermore,
the frequencies of CD4
+CD25
+FoxP3
+CD127
lo Treg in involved
lymphatic tissues were higher than those in PB and BM samples
from the same patients. The consequence of these overrepresented
CD4
+CD25
+FoxP3
+CD127
lo Treg in B-cell NHL remains un-
known. In solid tumors, it has been suggested that CD4
+CD25
+
Treg are crucial cellular mediators in immune evasion by
suppressing anti-tumor immunity and thereby contribute to the
growth of human tumors [14,15,17]. However, the high numbers of
intratumoral FoxP3
+ Treg were found to be correlated with
improved survival in germinal center-like DLBCL, follicular
lymphoma and classical Hodgkin’s lymphoma [29,30,31]. In this
study, we have shown that the Treg frequencies in PB were higher
in aggressive B-cell NHL than in indolent B-cell NHL. However, in
involved lymphatic tissues, there were no significant difference in
aggressive B-cell NHL and indolent B-cell NHL, indicating that the
enrichment of Treg in involved lymphatic tissues were not
associated with the lymphoid tissue types. We thought that
malignant B cells might invade PB in aggressive B-cell NHL, which
led to an increase in Treg frequency in PB.
Figure 3. Functional analysis of Treg from patients with B-cell NHL in vitro. (A) Fresh isolated Treg (CD4
+CD25
+ T cells) were cultured for
48 hours and then cocultured with CFSE-labeled CD4
+CD25
2 T cells for 4 days in the presence of c-irradiated (30 Gy) PBMCs, with each population
2610
5 cells. Proliferation was measured by levels of CFSE dilution using flow cytometric analysis. Histograms show the profile of CFSE-labeled
CD4
+CD25
2 T cells and the proliferated CD4
+CD25
2 T cells was measured by the percentage of CFSE
dim cells, as indicated. Treg could inhibit the
proliferation of allogeneic CD4
+CD25
2 T cells (
*P,0.01 vs CD4
+CD25
2 T cells only). The involved lymphatic tissues were reported as positive by
pathology in the same lymph nodes or spleen. The suppressive activity of Treg from involved lymphatic tissues was higher than those from PB or BM
in the same patients as well as those from HVs (
**P,0.01). One representative experiment of four was presented. (B) Involved lymphatic tissues from
patients with B-cell NHL were disaggregated into a single cell suspension and stimulated with PMA plus ionomycin for 5 hours in the presence of
BFA. Cells were subsequently costained with anti-CD3 and anti-CD8. Next, cells were fixed, permeabilized and stained with anti-FoxP3, anti-IL-2, anti-
IFN-c, anti-IL-4 or anti-IL-17. Dot plots were gated on CD3
+CD8
2 (CD3
+CD4
+) T cells, and the numbers within each quadrant represent the
percentages of CD4
+ T cells. The results suggested that Treg of involved lymphatic tissues from patients with B-cell NHL could not produce and secret
IL-2, IFN-c, IL-4 and IL-17. A representative of four independent experiments was showed.
doi:10.1371/journal.pone.0028649.g003
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+CD25
2 T cells, which partly depends on the
interaction of between PD-1 and B7-H1. (A,B) Malignant B cells, but not normal B cells, were able to induce FoxP3 expression in autologous
conventional T cells. CD4
+CD25
2 T cells were cultured for 5 days with X-ViVO
TM 15 medium alone or purified autologous B cells in the presence of
100 IU/ml IL-2. The cells were then harvested, stained, and analyzed for the percentage of CD4
+FoxP3
+ cells. The number in the dot plot represents
the percentage of gated cells expressing the relevant marker. Each open circle represents a single individual and numbers on the left of horizontal
bars represent the group means. The results were representative of seven independent experiments. (C,D) Malignant B cells, but not tumor-
infiltrating T cells, were able to induce the conversion of Treg from conventional T cells. CD4
+CD25
2 T cells isolated from involved lymphatic tissues
of B-cell NHL were co-cultured with normal B cells for 5 days. CD4
+CD25
2 T cells isolated from PB of HVs were co-cultured with malignant B cells for 5
days. (E) The expression of B7-H1 was higher in lymphoma B cells than normal B cells. Cells were costained with anti-CD19-FITC and anti-B7-H1-PE,
and then were analyzed the expression of B7-H1 on CD19
+ B cells using flow cytometry. (F,G) Histograms showed the effect of the interaction
between PD-1 and B7-H1 on the conversion of Treg from conventional T cells. CD4
+CD25
2 T cells were cocultured with autologous B cells purified
from patients with B-cell NHL for 5 days. Cells were treated with PD-1 fusion protein or anti-B7-H1 antibody as well as their corresponding controls in
the coculture system. A CD4
+FoxP3
+ gate was drawn based on their isotype controls. The results were representative of seven independent
experiments.
doi:10.1371/journal.pone.0028649.g004
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+CD25
+ cells in involved
lymphatic tissues displayed a higher ability to suppress the
proliferation of conventional CD4
+CD25
2 T cells than those in
PB or BM from patients as well as HVs. Furthermore, we have
shown that these Treg were unable to produce and secrete T
helper cytokines, suggesting that these cells accord to the classic
cytokine profile of Treg [32]. It has been observed that the
percentage of CD4
+FoxP3
+ cells increased in the co-culture of
conventional T cells with malignant B cells, suggesting that
malignant B cells can convert conventional CD4
+CD25
2 T cells
into Treg, which confirm and extend the observations by other
investigators [18,28,33]. Meanwhile, we have also demonstrated
that normal B cells did not have the ability to convert Treg under
our experimental conditions. In addition, we have shown that
these converted Treg were unable to produce T helper cytokines
and could markedly inhibit the proliferation of allogeneic
CD4
+CD25
2 T cells, which indicated that these converted Treg
had acquired the regulatory function. Combined with two
previous studies [34,35], which showed that gastric or ovarian
cancer cells could induce the conversion of CD4
+CD25
2 T cells
into CD4
+FoxP3
+ Treg in vitro, we thought that most cancer cells
might have the ability of the induction of Treg.
Because the suppressive function of Treg required cell-cell
contact, molecules expressed on the cell surface with suppressive
function are likely to play a key role in this process [36,37]. Our
results demonstrated that the expression levels of CTLA-4 and
GITR were higher in patients with B-cell NHL than those in HVs,
suggesting that CTLA-4 and GITR may be involved in
modulating suppressive capacity of Treg in human, which might
be one of the reasons of higher suppressive ability of Treg from
Figure 5. Functional analysis of induced FoxP3-expressing CD4 cells in vitro. (A) CD4
+CD25
2 cells isolated from a patient with B-cell NHL
were co-cultured with purified autologous B cells for 5 days. Then, CD4
+CD25
+ T cells were isolated and cocultured with CFSE-labeled CD4
+CD25
2 T
cells for 4 days in the presence of c-irradiated (30 Gy) PBMCs, with each population 2610
5 cells. Histograms showed the profile of CFSE-labeled
CD4
+CD25
2 T cells and the proliferated CD4
+CD25
2 T cells was measured by the percentage of CFSE
dim cells, as indicated. The converted Treg could
inhibit the proliferation of allogeneic CD4
+CD25
2 T cells (P,0.01). Two BM samples (patients 8 and 11) and one LN sample (patient 24) were tested,
and a representative experiment of three was presented. (B) CD4
+CD25
2 cells isolated from a HV or patient with B-cell NHL were co-cultured with
purified respective autologous B cells for 5 days. Then, the cells were stimulated with PMA plus ionomycin for 5 hours in the presence of BFA. Cells
were harvested and costained with anti-CD3 and anti-CD8. Next, cells were fixed, permeabilized and stained with anti-FoxP3, anti-IL-2, anti-IFN-c,
anti-IL-4, or anti-IL-17. Dot plots were gated on CD3
+CD4
+(CD3
+CD8
2) T cells, and the numbers within each quadrant represent the percentages of
CD4
+ T cells. Two BM samples (patients 8 and 11) and one LN sample (patient 24) were tested, and the results were representatives of three
independent experiments.
doi:10.1371/journal.pone.0028649.g005
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blocking of these two receptors on Treg can abrogate the
suppressive function, increase anti-tumor immune responses and
cause tumor recession [38,39]. Interaction between PD-1 and B7-
H1 results in inhibition of T cell proliferation and cytokine
production, which forms a molecular shield to prevent destruction
by cytotoxic T cells and remains a weak proliferation of Treg
[40,41]. We have shown that the expression of PD-1 on
CD4
+CD25
+ Treg was higher in patients with B-cell NHL than
in HVs, which strongly suggested a role for PD-1 and B7-H1
interaction in Treg cell-mediated suppression in B-cell NHL. In
involved lymphatic tissues, PD-1 was mainly expressed on the
CD4
+CD25
2 cells, but not on Treg. Blocking the interaction of
PD-1 and B7-H1 could reduce the conversion of Treg induced by
malignant B cells in some cases of patients with B-cell NHL, which
indicated that the Treg conversion of CD4
+CD25
2 T cells might
be mediated through the PD-1/B7-H1 pathway.
In summary, we have showed an increased frequency and
suppressive activity of CD4
+CD25
+FoxP3
+CD127
lo Treg in PB,
BM, and involved lymphatic tissues from patients with B-cell
NHL, which might play a critical role in suppressing the host
immune responses to tumor. Furthermore, we have also showed
that malignant B cells possessed the intrinsic properties to induce
the conversion of Treg from CD4
+CD25
2 T cells, which partly
through the PD-1/B7-H1 pathway. Thus, these findings open new
clues to study Treg biology related to tumor occurrence and
provide novel insights into the design of immunotherapeutic
strategies for B-cell NHL.
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